EZH2 accounts for 2.4% of the total number of mutations analysed for adult AML in the OncoPrint [51] (datasets included are from Beat AML [35] and The Cancer Genome Atlas (TCGA) Research Network (2013–2018) [52,53]), while mutations of other core factors SUZ12, EED and RBBP4 contribute 1.5, 0.7 and 0.5% to the data, respectively. This evidence concerns the gene EZH2 and acute myeloid leukemia.